• Home
  • » 
  • Reports
  • » 
  • Point-of-Care Diagnostics Market for Inf...

Point-of-Care Diagnostics Market

Point-of-Care Diagnostics Market for Infectious Diseases by Indication, Type of Technology and Key Geographical Region (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2025

  • Lowest Price Guaranteed From USD 4,899

  • Published
    September 2020

  • Pages
    274

  • View Count
    11753

  • Buy Now

Example Insights

This image highlights the context of Point of Care Diagnostics for Infectious Diseases Market report. Over time, innovation in bioanalytical techniques, biosensors, and the introduction of lab-on-a-chip technologies, have enabled the development of versatile point-of-care diagnostics, which facilitate better disease diagnosis, monitoring, and management This image presents current market landscape of Point of Care Diagnostics. Nearly 1,600 point-of-care diagnostic solutions for infectious disorders are at various stages of development; in fact, the portfolio of several developers includes point-of-care tests for the diagnosis of multiple indications This image provides list of Point of Care Diagnostics. Amidst other initiatives, companies have recently demonstrated a focused approach towards the development of point-of-care diagnostics for novel coronavirus (SARS-CoV-2 strain)
This image provides list of Point of Care Diagnostics. The market for HIV/AIDS and hepatitis as well as respiratory infections features the presence of seasoned industry veterans and recent players, offering tests and devices for the diagnosis of target indications This image presents current market landscape of Point of Care Diagnostics for Infectious Diseases. A number of solutions are now available for the diagnosis of infectious diseases and are based on multiple types of analytes, depending on the type of clinical condition This image highlights the geographical distribution of Point of Care Diagnostic Developers. Majority of the stakeholders in this competitive market are small / mid-sized firms, offering a variety of products for the diagnosis of target disease indications
This image highlights the partnership activity undertaken by players engaged in Point of Care Diagnostics Market. The rising interest in this field is reflected by the increase in partnership activity in the recent past, involving both international and indigenous stakeholders focused on distribution of POC tests / technologies This image describes the potential acquisition targets. In fact, an evaluation of 275+ stakeholders engaged in the development of POCDs for infectious diseases revealed the existence of several likely acquisition targets, across different geographical regions This image highlights the market segments of Point of Care Diagnostics Market for Infectious Diseases. The market is likely to grow at a CAGR of ~12%; the anticipated opportunity is expected to be distributed across various types of infectious diseases, type of technology and geographies

Report Description

Point-of-Care Diagnostics Market Overview

The point-of-care diagnostics market for infectious diseases is likely to be worth $1,986 million in 2025. According to the World Health Organization (WHO), the big three infectious diseases, namely human immunodeficiency virus / acquired immunodeficiency syndrome (HIV / AIDS), malaria and tuberculosis (TB), are reported to be the cause of approximately 2.5 million annual fatalities worldwide. Moreover, the pathogens responsible for causing these diseases are known to undergo selective mutations, which make them resistant to commonly used antibiotics. This impedes the effective treatment of the aforementioned clinical conditions. Since the pathophysiology of such diseases is known to evolve with time, better diagnostic tools with high sensitivity and specificity are required for timely diagnosis and better treatment related decision-making. For diseases of bacterial origin, diagnosis is based on culturing the pathogen; this is considered the current gold standard. Although these methods are highly specific, they are time consuming, requiring three to five days for detecting the responsible pathogen. On the other hand, in case of viral infections, molecular diagnostic platforms, such as next generation sequencing and real-time polymerase chain reactions, are typically used. However, these molecular level analytical techniques are expensive, complicated, and generally inaccessible in resource-limited settings. 

Given the aforementioned challenges, the medical industry is consistently engaged in efforts to innovate in assay formats, developing better biosensors, and bioanalytical platforms to expedite the diagnosis process. The concept of point-of-care diagnostics, or rapid diagnostics, has become even more popular with the novel coronavirus outbreak. Unlike the traditional laboratory-based tests, the results of a point-of-care test can be made available instantaneously (as fast as 5 minutes). This facilitates faster diagnosis and prompt decision making with respect to treatment, thereby, enabling the containment of infectious diseases at an early stage of transmission and preventing outbreaks. Additionally, point-of-care diagnostics have shown to reduce the reliance on presumptive treatment, thereby, helping curb the inappropriate use of antibiotics. Till date, point-of-care diagnostics are widely used for the diagnosis of diseases, such as chikungunya, COVID-19, dengue, hepatitis, malaria, pneumonia, and tuberculosis. In future, we expect such tests / assays to dominate the in vitro diagnostics market.

Recent Developments in Point of Diagnostic Care Market:

Several recent developments have taken place in the field of point of diagnostic care. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In May 2023, Molbio Diagnostics entered into a collaboration with ShanMukha to design, develop and commercialize point-of-care diagnostic devices to diagnose hemoglobin-related diseases. 
  • In August 2023, CrisprBits in collaboration with MolBio Diagnostics launched point-of-care CRISPR-based tests.

Scope of the Report

The ‘Point-of-Care Diagnostics Market for Infectious Diseases, 2020-2025’ report features an extensive study on point-of-care diagnostics that are either commercialized or are under development for diagnosis of different types of infections. In addition, it features an elaborate discussion on the likely future opportunity associated with such tools, over the next five years. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of point-of-care diagnostics for COVID-19, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), type of sample (blood, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of Point-of-Care Diagnostics for tropical diseases, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indication (chikungunya, dengue, Ebola, malaria, and zika), type of sample (blood, sputum, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of point-of-care diagnostics for respiratory infections, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indication (influenza, pneumonia, and tuberculosis), type of sample (blood, cerebrospinal fluid, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed review of the overall landscape of point-of-care diagnostics for HIV/AIDS and hepatitis, providing information on current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indication (hepatitis A, hepatitis B, hepatitis C, and HIV/AIDS), type of sample (blood, feces, oral fluid, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the report presents the details of the companies developing these point-of-care diagnostics, including information on year of establishment, company size and location of headquarters.
  • A detailed study of the overall landscape of point-of-care diagnostics for infectious diseases, featuring analyses based on a number of relevant parameters, such as type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indication (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes).
  • An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between January 2018 and July 2020, covering distribution and supply agreements, product development and commercialization agreements, commercialization agreements, mergers and acquisitions, product development and manufacturing agreements, research and development agreements, and product / technology integration agreements.
  • A detailed analysis on acquisition targets, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2018, and offering a means for other industry stakeholders to identify potential acquisition targets.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities. Based on various parameters, such as number of available / under development products, average price of point-of-care tests and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2020-2025. The report also features the likely distribution of the current and forecasted opportunity across [A] target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), [B] type of technology (lateral flow, molecular diagnostics, fluorescence immunoassay, solid phase, and others), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Reuven Duer, Founder and CEO, Proactive Diagnostics
  • Giffin Daughtridge, CEO, UrSure
  • Abhinav Thakur, Managing Director, Accurex Biomedical
  • Gerrit Van Roekel, Director of Business Development, Hemex Health
  • Sofiane Bennacer, Business Development Manager, Credo Diagnostics Biomedical

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent trends within the point-of-care diagnostics market?
  • What are the key technologies being used in point-of-care diagnostics?
  • Who are the leading developers of point-of-care diagnostics for COVID-19?
  • Who are the leading developers of point-of-care diagnostics for tropical diseases (chikungunya, dengue, Ebola, malaria, and zika) and respiratory infections (influenza, pneumonia, and tuberculosis)?
  • Who are the leading developers of point-of-care diagnostics for HIV/AIDS and hepatitis?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographical regions?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for point-of-care diagnostics for infectious diseases and its likely evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to point-of-care diagnostics. In addition, the chapter discusses the growing incidence of infectious diseases worldwide, elaborating on the importance of point-of-care diagnostics for early and accurate diagnosis. It also highlights the characteristics of an ideal point-of-care diagnostic and the various technology platforms that are currently being used for development of such tests. It also features a brief discussion on the opportunities and the likely future trends in this field. 

Chapter 4 provides information on nearly 180 point-of-care diagnostics that are either available or being developed for the diagnosis of COVID-19, and a detailed analysis based on a number of relevant parameters, such as current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), type of sample (blood, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the chapter includes an analysis of the companies engaged in developing point-of-care diagnostics for COVID-19, based on year of establishment, company size and location of headquarters.

Chapter 5 provides information on nearly 515 point-of-care diagnostics that are either available or being developed for the diagnosis of tropical diseases, and a detailed analysis based on a number of relevant parameters, such as current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indications (chikungunya, dengue, Ebola, malaria, and zika), type of sample (blood, sputum, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the chapter includes an analysis of the companies engaged in developing point-of-care diagnostics for tropical diseases, based on year of establishment, company size and location of headquarters.

Chapter 6 provides information on nearly 280 point-of-care diagnostics that are either available or being developed for the diagnosis of respiratory infections, and a detailed analysis based on a number of relevant parameters, such as current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, and others), target disease indications (influenza, pneumonia, and tuberculosis), type of sample (blood, cerebrospinal fluid, nasal / nasopharyngeal secretions, sputum, urine, and others), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the chapter includes an analysis of the companies engaged in developing point-of-care diagnostics for respiratory infections, based on year of establishment, company size and location of headquarters.

Chapter 7 provides information on nearly 610 point-of-care diagnostics that are either available or being developed for the diagnosis of HIV/AIDS and hepatitis, and a detailed analysis based on a number of relevant parameters, such as current development status of point-of-care diagnostics (under development, research use only, and available), type of product (test and device / platform), type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indications (hepatitis A, hepatitis B, hepatitis C, and HIV/AIDS), type of sample (blood, feces, oral fluid, and urine), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes). In addition, the chapter includes an analysis of the companies engaged in developing point-of-care diagnostics for HIV/AIDS and hepatitis, based on year of establishment, company size and location of headquarters.

Chapter 8 presents a study of the current market landscape of point-of-care diagnostics for infectious diseases, featuring detailed analyses based on parameters, such as type of technology (flow-through, fluorescence immunoassay, lateral flow, molecular diagnostics, solid phase, vertical flow, and others), target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), sensitivity range (<90%, 90-95%, and >95%), specificity range (<90%, 90-95%, and >95%), and turnaround time (≤5 minutes, >5-15 minutes, >15-30 minutes, and >30 minutes).

Chapter 9 features an analysis of the various partnerships and collaborations that have been inked by stakeholders in this domain, during 2018-2020. It includes a brief description of partnership models (such as distribution and supply agreements, product development and commercialization agreements, commercialization agreements, mergers and acquisitions, product development and manufacturing agreements, research and development agreements, and product / technology integration agreements) adopted by the stakeholders. In addition, it includes analyses based on year of partnership, type of partnership, type of product, target disease indication, and geographical location of companies involved.

Chapter 10 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2018, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 11 features an insightful market forecast analysis, highlighting the likely growth of point-of-care diagnostics for infectious diseases market, till the year 2025. In order to provide details on the future opportunity, our projections have been segmented on the basis [A] target disease indications (chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika), [B] type of technology (lateral flow assay, molecular diagnostics, fluorescence immunoassay, solid phase assay, and others), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Reuven Duer (Founder and CEO, Proactive Diagnostics), Giffin Daughtridge (CEO, UrSure), Abhinav Thakur (Managing Director, Accurex Biomedical), Gerrit Van Roekel (Director of Business Development, Hemex Health), and Sofiane Bennacer (Business Development Manager, Credo Diagnostics Biomedical).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the point-of-care diagnostics industry. 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Point-of-Care Diagnostics (POCDs)
3.2.1. Characteristics of an Ideal Point-of-Care Diagnostic
3.2.2. Technologies Used in Point-of-Care Diagnostics of Infectious Diseases
3.3. Challenges Associated with Point-of-Care Diagnostics
3.4. Future Perspectives

4. CURRENT MARKET LANDSCAPE (FOCUS ON COVID-19)
4.1. Chapter Overview
4.2. Point-of-Care Diagnostics for COVID-19: List of Products
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Product
4.2.3. Analysis by Type of Technology
4.2.4. Analysis by Type of Sample
4.2.5. Analysis by Sensitivity Range
4.2.6. Analysis by Specificity Range
4.2.7. Analysis by Turnaround Time

4.3. Point-of-Care Diagnostics for COVID-19: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.3.3. Leading Developers: Analysis by Number of Products
4.3.4. World Map Representation: Analysis by Regional Activity

5. CURRENT MARKET LANDSCAPE (FOCUS ON TROPICAL DISEASES)
5.1. Chapter Overview
5.2. Point-of-Care Diagnostics for Tropical Diseases: List of Products
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Type of Product
5.2.3. Analysis by Type of Technology
5.2.4. Analysis by Target Disease Indication
5.2.5. Analysis by Type of Sample
5.2.6. Analysis by Sensitivity Range
5.2.7. Analysis by Specificity Range
5.2.8. Analysis by Turnaround Time

5.3. Point-of-Care Diagnostics for Tropical Diseases: List of Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size and Geographical Location
5.3.3. Leading Developers: Analysis by Number of Products
5.3.4. World Map Representation: Analysis by Regional Activity

6. CURRENT MARKET LANDSCAPE (FOCUS ON RESPIRATORY INFECTIONS)
6.1. Chapter Overview
6.2. Point-of-Care Diagnostics for Respiratory Infections: List of Products
6.2.1. Analysis by Status of Development
6.2.2. Analysis by Type of Product
6.2.3. Analysis by Type of Technology
6.2.4. Analysis by Target Disease Indication
6.2.5. Analysis by Type of Sample
6.2.6. Analysis by Sensitivity Range
6.2.7. Analysis by Specificity Range
6.2.8. Analysis by Turnaround Time

6.3. Point-of-Care Diagnostics for Respiratory Infections: List of Developers
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size and Geographical Location
6.3.3. Leading Developers: Analysis by Number of Products
6.3.4. World Map Representation: Analysis by Regional Activity

7. CURRENT MARKET LANDSCAPE (FOCUS ON HIV/AIDS AND HEPATITIS)
7.1. Chapter Overview
7.2. Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Products
7.2.1. Analysis by Status of Development
7.2.2. Analysis by Type of Product
7.2.3. Analysis by Type of Technology
7.2.4. Analysis by Target Disease Indication
7.2.5. Analysis by Type of Sample
7.2.6. Analysis by Sensitivity Range
7.2.7. Analysis by Specificity Range
7.2.8. Analysis by Turnaround Time

7.3. Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size and Geographical Location
7.3.3. Leading Developers: Analysis by Number of Products
7.3.4. World Map Representation: Analysis by Regional Activity

8. OVERALL MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Analysis by Type of Technology
8.3. Analysis by Target Disease Indication
8.4. Analysis by Sensitivity Range
8.5. Analysis by Specificity Range
8.6. Analysis by Turnaround Time

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Point-of-Care Diagnostics for Infectious Diseases: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Product
9.3.4. Analysis by Target Disease Indication
9.3.5. Analysis by Year and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental Agreements

10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets in North America
10.5. Potential Strategic Acquisition Targets in Europe
10.6. Potential Strategic Acquisition Targets in Asia-Pacific
10.7. Potential Strategic Acquisition Targets in Latin America
10.8. Potential Strategic Acquisition Targets in Middle East, North Africa, and Rest of the World
10.9. Concluding Remarks

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020-2025
11.4. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication
11.4.1. Point-of-Care Diagnostics Market for COVID-19, 2020-2025
11.4.2. Point-of-Care Diagnostics Market for Chikungunya, 2020-2025
11.4.3. Point-of-Care Diagnostics Market for Dengue, 2020-2025
11.4.4. Point-of-Care Diagnostics Market for Ebola, 2020-2025
11.4.5. Point-of-Care Diagnostics Market for Hepatitis, 2020-2025
11.4.6. Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025
11.4.7. Point-of-Care Diagnostics Market for Influenza, 2020-2025
11.4.8. Point-of-Care Diagnostics Market for Malaria, 2020-2025
11.4.9. Point-of-Care Diagnostics Market for Pneumonia, 2020-2025
11.4.10. Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025
11.4.11. Point-of-Care Diagnostics Market for Zika, 2020-2025

11.5. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology
11.5.1. Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025
11.5.2. Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025
11.5.3. Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025
11.5.4. Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025
11.5.5. Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025

11.6. Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography
11.6.1. Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025
11.6.2. Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025
11.6.3. Point-of-Care Diagnostics for Infectious Diseases Market in the UK, 2020-2025
11.6.4. Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025
11.6.5. Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025
11.6.6. Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025
11.6.7. Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025
11.6.8. Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025
11.6.9. Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025
11.6.10. Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025
11.6.11. Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025
11.6.12. Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025
11.6.13. Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025
11.6.14. Point-of-Care Diagnostics for Infectious Diseases Market in Saudi Arabia, 2020-2025
11.6.15. Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025
11.6.16. Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025
11.6.17. Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview

12.2. Proactive Diagnostics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Reuven Duer, Founder and Chief Executive Officer

12.3. UrSure
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Giffin Daughtridge, Chief Executive Officer

12.4. Accurex Biomedical
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Abhinav Thakur, Managing Director

12.5. Hemex Health
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Gerrit Van Roekel, Director of Business Development

12.6. Credo Diagnostics Biomedical
12.6.1. Company Snapshot
12.6.2. Interview Transcript: Sofiane Bennacer, Business Development Manager

13. CONCLUDING REMARKS
 
14. APPENDIX 1: TABULATED DATA
 
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 The ASSURED Criteria for an Ideal Point-of-Care Diagnostics
Figure 3.2 Technologies Used in Point-of-Care Diagnostics for Infectious Diseases
Figure 4.1 Point-of-Care Diagnostics for COVID-19: Distribution by Status of Development
Figure 4.2 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Product
Figure 4.3 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Technology
Figure 4.4 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Sample
Figure 4.5 Point-of-Care Diagnostics for COVID-19: Distribution by Sensitivity Range
Figure 4.6 Point-of-Care Diagnostics for COVID-19: Distribution by Specificity Range
Figure 4.7 Point-of-Care Diagnostics for COVID-19: Distribution by Turnaround Time
Figure 4.8 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Year of Establishment
Figure 4.9 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Company Size and Geographical Location
Figure 4.10 Leading Players: Distribution by Number of Products
Figure 4.11 World Map Representation: Distribution by Regional Activity
Figure 5.1 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Status of Development
Figure 5.2 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Product
Figure 5.3 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Technology
Figure 5.4 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Target Disease Indication
Figure 5.5 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Sample
Figure 5.6 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Sensitivity Range
Figure 5.7 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Specificity Range
Figure 5.8 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Turnaround Time
Figure 5.9 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Year of Establishment
Figure 5.10 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Company Size and Geographical Location
Figure 5.11 Leading Players: Distribution by Number of Products
Figure 5.12 World Map Representation: Distribution by Regional Activity
Figure 6.1 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Status of Development
Figure 6.2 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Product
Figure 6.3 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Technology
Figure 6.4 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Target Disease Indication
Figure 6.5 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Sample
Figure 6.6 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Sensitivity Range
Figure 6.7 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Specificity Range
Figure 6.8 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Turnaround Time
Figure 6.9 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Year of Establishment
Figure 6.10 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Company Size and Geographical Location
Figure 6.11 Leading Players: Distribution by Number of Products
Figure 6.12 World Map Representation: Distribution by Regional Activity
Figure 7.1 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Status of Development
Figure 7.2 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Product
Figure 7.3 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Technology
Figure 7.4 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Target Disease Indication
Figure 7.5 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Sample
Figure 7.6 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Sensitivity Range
Figure 7.7 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Specificity Range
Figure 7.8 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Turnaround Time
Figure 7.9 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Year of Establishment
Figure 7.10 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Company Size and Geographical Location
Figure 7.11 Leading Players: Distribution by Number of Products
Figure 7.12 World Map Representation: Distribution by Regional Activity
Figure 8.1 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Type of Technology
Figure 8.2 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Target Disease Indication
Figure 8.3 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Sensitivity Range
Figure 8.4 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Specificity Range
Figure 8.5 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Turnaround Time
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2020 (till July)
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 9.6 Partnerships and Collaborations: Distribution by Target Disease Indication
Figure 9.7 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 9.8 Most Active Players: Distribution by Number of Partnerships
Figure 9.9 Partnerships and Collaborations: Regional Distribution
Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.1 Likely Acquisition Targets: Geographical Distribution
Figure 11.1 Global Point-of-Care for Infectious Diseases Market, 2020-2025 (USD Million)
Figure 11.2 Global Point-of-Care for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication (USD Million)
Figure 11.3 Point-of-Care Diagnostics Market for COVID-19, 2020-2025 (USD Million)
Figure 11.4 Point-of-Care Diagnostics Market for Chikungunya, 2020-2025 (USD Million)
Figure 11.5 Point-of-Care Diagnostics Market for Dengue, 2020-2025 (USD Million)
Figure 11.6 Point-of-Care Diagnostics Market for Ebola, 2020-2025 (USD Million)
Figure 11.7 Point-of-Care Diagnostics Market for Hepatitis, 2020-2025 (USD Million)
Figure 11.8 Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025 (USD Million)
Figure 11.9 Point-of-Care Diagnostics Market for Influenza, 2020-2025 (USD Million)
Figure 11.10 Point-of-Care Diagnostics Market for Malaria, 2020-2025 (USD Million)
Figure 11.11 Point-of-Care Diagnostics Market for Pneumonia, 2020-2025 (USD Million)
Figure 11.12 Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025 (USD Million)
Figure 11.13 Point-of-Care Diagnostics Market for Zika, 2020-2025 (USD Million)
Figure 11.14 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology (USD Million)
Figure 11.15 Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025 (USD Million)
Figure 11.16 Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025 (USD Million)
Figure 11.17 Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025 (USD Million)
Figure 11.18 Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025 (USD Million)
Figure 11.19 Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025 (USD Million)
Figure 11.20 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography (USD Million)
Figure 11.21 Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025 (USD Million)
Figure 11.22 Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025 (USD Million)
Figure 11.23 Point-of-Care Diagnostics for Infectious Diseases Market in the UK, 2020-2025 (USD Million)
Figure 11.24 Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025 (USD Million)
Figure 11.25 Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025 (USD Million)
Figure 11.26 Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025 (USD Million)
Figure 11.27 Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025 (USD Million)
Figure 11.28 Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025 (USD Million)
Figure 11.29 Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025 (USD Million)
Figure 11.30 Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025 (USD Million)
Figure 11.31 Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025 (USD Million)
Figure 11.32 Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025 (USD Million)
Figure 11.33 Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025 (USD Million)
Figure 11.34 Point-of-Care Diagnostics for Infectious Diseases in Saudi Arabia, 2020-2025 (USD Million)
Figure 11.35 Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025 (USD Million)
Figure 11.36 Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025 (USD Million)
Figure 11.37 Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025 (USD Million)

List Of Tables

 Table 4.1 Point-of-Care Diagnostics for COVID-19: List of Products
Table 4.2 Point-of-Care Diagnostics for COVID-19: List of Developers
Table 5.1 Point-of-Care Diagnostics for Tropical Diseases: List of Products
Table 5.2 Point-of-Care Diagnostics for Tropical Diseases: List of Developers
Table 6.1 Point-of-Care Diagnostics for Respiratory Infections: List of Products
Table 6.2 Point-of-Care Diagnostics for Respiratory Infections: List of Developers
Table 7.1 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Products
Table 7.2 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: List of Developers
Table 9.1 Point-of-Care Diagnostics for Infectious Diseases: List of Partnerships and Collaborations
Table 10.1 North America: Likely Targets for Acquisition
Table 10.2 Europe: Likely Targets for Acquisition
Table 10.3 Asia-Pacific: Likely Targets for Acquisition
Table 10.4 Latin America: Likely Targets for Acquisition
Table 10.5 Middle East, North Africa, and Rest of the World: Likely Targets for Acquisition
Table 12.1 Proactive Diagnostics: Company Snapshot
Table 12.2 UrSure: Company Snapshot
Table 12.3 Accurex Biomedical: Company Snapshot
Table 12.4 Hemex Health: Company Snapshot
Table 12.5 Credo Diagnostics Biomedical: Company Snapshot
Table 14.1 Point-of-Care Diagnostics for COVID-19: Distribution by Status of Development
Table 14.2 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Product
Table 14.3 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Technology
Table 14.4 Point-of-Care Diagnostics for COVID-19: Distribution by Type of Sample
Table 14.5 Point-of-Care Diagnostics for COVID-19: Distribution by Sensitivity Range
Table 14.6 Point-of-Care Diagnostics for COVID-19: Distribution by Specificity Range
Table 14.7 Point-of-Care Diagnostics for COVID-19: Distribution by Turnaround Time
Table 14.8 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Year of Establishment
Table 14.9 Point-of-Care Diagnostics for COVID-19: Distribution of Developers by Company Size and Geographical Location
Table 14.10 Leading Players: Distribution by Number of Products
Table 14.11 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Status of Development
Table 14.12 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Product
Table 14.13 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Technology
Table 14.14 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Target Disease Indication
Table 14.15 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Type of Sample
Table 14.16 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Sensitivity Range
Table 14.17 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Specificity Range
Table 14.18 Point-of-Care Diagnostics for Tropical Diseases: Distribution by Turnaround Time
Table 14.19 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Year of Establishment
Table 14.20 Point-of-Care Diagnostics for Tropical Diseases: Distribution of Developers by Company Size and Geographical Location
Table 14.21 Leading Players: Distribution by Number of Products
Table 14.22 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Status of Development
Table 14.23 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Product
Table 14.24 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Technology
Table 14.25 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Target Disease Indication
Table 14.26 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Type of Sample
Table 14.27 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Sensitivity Range
Table 14.28 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Specificity Range
Table 14.29 Point-of-Care Diagnostics for Respiratory Infections: Distribution by Turnaround Time
Table 14.30 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Year of Establishment
Table 14.31 Point-of-Care Diagnostics for Respiratory Infections: Distribution of Developers by Company Size and Geographical Location
Table 14.32 Leading Players: Distribution by Number of Products
Table 14.33 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Status of Development
Table 14.34 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Product
Table 14.35 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Technology
Table 14.36 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Target Disease Indication
Table 14.37 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Type of Sample
Table 14.38 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Sensitivity Range
Table 14.39 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Specificity Range
Table 14.40 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution by Turnaround Time
Table 14.41 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Year of Establishment
Table 14.42 Point-of-Care Diagnostics for HIV/AIDS and Hepatitis: Distribution of Developers by Company Size and Geographical Location
Table 14.43 Leading Players: Distribution by Number of Products
Table 14.44 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Type of Technology
Table 14.45 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Target Disease Indication
Table 14.46 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Sensitivity Range
Table 14.47 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Specificity Range
Table 14.48 Point-of-Care Diagnostics for Infectious Diseases: Distribution by Turnaround Time
Table 14.49 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2020 (till July)
Table 14.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.51 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 14.52 Partnerships and Collaborations: Distribution by Type of Product
Table 14.53 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 14.54 Partnerships and Collaborations: Distribution by Target Disease Indication
Table 14.55 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 15.56 Most Active Players: Distribution by Number of Partnerships
Table 14.57 Partnerships and Collaborations: Regional Distribution
Table 14.58 Likely Acquisition Targets: Geographical Distribution
Table 14.59 Global Point-of-Care for Infectious Diseases Market, 2020-2025 (USD Million)
Table 14.60 Global Point-of-Care for Infectious Diseases Market, 2020 and 2025: Distribution by Target Disease Indication (USD Million)
Table 14.61 Point-of-Care Diagnostics Market for COVID-19, 2020-2025 (USD Million)
Table 14.62 Point-of-Care Diagnostics Market for Chikungunya, 2020-2025 (USD Million)
Table 14.63 Point-of-Care Diagnostics Market for Dengue, 2020-2025 (USD Million)
Table 14.64 Point-of-Care Diagnostics Market for Ebola, 2020-2025 (USD Million)
Table 14.65 Point-of-Care Diagnostics Market for Hepatitis, 2020-2025 (USD Million)
Table 14.66 Point-of-Care Diagnostics Market for HIV/AIDS, 2020-2025 (USD Million)
Table 14.67 Point-of-Care Diagnostics Market for Influenza, 2020-2025 (USD Million)
Table 14.68 Point-of-Care Diagnostics Market for Malaria, 2020-2025 (USD Million)
Table 14.69 Point-of-Care Diagnostics Market for Pneumonia, 2020-2025 (USD Million)
Table 14.70 Point-of-Care Diagnostics Market for Tuberculosis, 2020-2025 (USD Million)
Table 14.71 Point-of-Care Diagnostics Market for Zika, 2020-2025 (USD Million)
Table 14.72 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Type of Technology (USD Million)
Table 14.73 Point-of-Care Diagnostics for Infectious Diseases Market for Lateral Flow Assay, 2020-2025 (USD Million)
Table 14.74 Point-of-Care Diagnostics for Infectious Diseases Market for Molecular Diagnostics, 2020-2025 (USD Million)
Table 14.75 Point-of-Care Diagnostics for Infectious Diseases Market for Fluorescence Immunoassay, 2020-2025 (USD Million)
Table 14.76 Point-of-Care Diagnostics for Infectious Diseases Market for Solid Phase Assay, 2020-2025 (USD Million)
Table 14.77 Point-of-Care Diagnostics for Infectious Diseases Market for Other Technologies, 2020-2025 (USD Million)
Table 14.78 Global Point-of-Care Diagnostics for Infectious Diseases Market, 2020 and 2025: Distribution by Geography (USD Million)
Table 14.79 Point-of-Care Diagnostics for Infectious Diseases Market in the US, 2020-2025 (USD Million)
Table 14.80 Point-of-Care Diagnostics for Infectious Diseases Market in Canada, 2020-2025 (USD Million)
Table 14.81 Point-of-Care Diagnostics for Infectious Diseases in the UK, 2020-2025 (USD Million)
Table 14.82 Point-of-Care Diagnostics for Infectious Diseases Market in Germany, 2020-2025 (USD Million)
Table 14.83 Point-of-Care Diagnostics for Infectious Diseases Market in Spain, 2020-2025 (USD Million)
Table 14.84 Point-of-Care Diagnostics for Infectious Diseases Market in France, 2020-2025 (USD Million)
Table 14.85 Point-of-Care Diagnostics for Infectious Diseases Market in Italy, 2020-2025 (USD Million)
Table 14.86 Point-of-Care Diagnostics for Infectious Diseases Market in China, 2020-2025 (USD Million)
Table 14.87 Point-of-Care Diagnostics for Infectious Diseases Market in India, 2020-2025 (USD Million)
Table 14.88 Point-of-Care Diagnostics for Infectious Diseases Market in Japan, 2020-2025 (USD Million)
Table 14.89 Point-of-Care Diagnostics for Infectious Diseases Market in Australia, 2020-2025 (USD Million)
Table 14.90 Point-of-Care Diagnostics for Infectious Diseases Market in Brazil, 2020-2025 (USD Million)
Table 14.91 Point-of-Care Diagnostics for Infectious Diseases Market in Argentina, 2020-2025 (USD Million)
Table 14.92 Point-of-Care Diagnostics for Infectious Diseases Market in Saudi Arabia, 2020-2025 (USD Million)
Table 14.93 Point-of-Care Diagnostics for Infectious Diseases Market in UAE, 2020-2025 (USD Million)
Table 14.94 Point-of-Care Diagnostics for Infectious Diseases Market in Egypt, 2020-2025 (USD Million)
Table 14.95 Point-of-Care Diagnostics for Infectious Diseases Market in South Africa, 2020-2025 (USD Million)

List Of Companies

  1. 3M Health Care
  2. A. Menarini Diagnostics
  3. AAZ-LMB
  4. Abacus Diagnostica
  5. Abingdon Health
  6. Abionic
  7. Accel Diagnostics
  8. Access Bio
  9. AccuBioTech
  10. Accurex Biomedical
  11. Achira Labs
  12. ACON Laboratories
  13. Acro Biotech
  14. Actionmed Medical Equipment Trading
  15. ADS Biotec
  16. ADVAITE
  17. Advy Chemical
  18. AgPlus Diagnostics
  19. Aidian
  20. AIL Dixon Technologies
  21. AKO MED
  22. Akonni Biosystems
  23. ALAB
  24. Alere
  25. AlphaSIP Laboratories
  26. ALUXBIO
  27. American Bio Medica
  28. American Leprosy Missions
  29. American Screening
  30. AMS UK
  31. Anamol Laboratories
  32. Anhui DeepBlue Medical Technology
  33. Antagen Pharmaceuticals
  34. Anteo Diagnostics
  35. ApolloDx
  36. Aquila Diagnostic Systems
  37. Arbor Vita
  38. ArcDia International
  39. ARKRAY
  40. ARKRAY Healthcare
  41. Artron Laboratories
  42. Asan Pharmaceutical
  43. Ativa Medical
  44. Atlas Link
  45. Atlas Medical
  46. Atomo Diagnostics
  47. Augurix
  48. Autobio Diagnostics
  49. Avacta
  50. Aviana Molecular Technologies
  51. Axxin
  52. Aytu BioScience
  53. BBI Solutions
  54. Becton, Dickinson
  55. Bedford Biotech Nigeria
  56. Beijing Hotgen Biotech
  57. Beijing Kewei Clinical Diagnostic Reagent
  58. Beijing Wantai Biological Pharmacy
  59. BGI Group
  60. Bhat Bio-tech India
  61. BHR Pharmaceuticals
  62. Biko
  63. binx health
  64. BioFab
  65. BioFire Diagnostics
  66. Biofootprints Healthcare
  67. Biogate Laboratories
  68. BIOgenetiX
  69. Biolidics
  70. bioLytical Laboratories
  71. Bio-Manguinhos
  72. Biomedical Advanced Research and Development Authority (BARDA)
  73. BioMedomics
  74. Biomeme
  75. bioMérieux
  76. Bionor
  77. Biopanda Reagents
  78. BioPorto Diagnostics
  79. Bio-Rad Laboratories
  80. Biosensia
  81. Biosensorix
  82. BioSpeedia
  83. BioSure (UK)
  84. biosurfit
  85. Biosynex
  86. Biotec Laboratories
  87. Biozek medical
  88. BluSense Diagnostics
  89. Boditech Med
  90. Bosch Healthcare Solutions
  91. Brevitest Technologies
  92. Bright Machines
  93. Broad Institute
  94. BTNX
  95. Bundi International Diagnostics
  96. Calypte Biomedical
  97. Calyx Biotech
  98. Canon Medical Systems
  99. Carpegen
  100. Cascade Biosystems
  101. Cavidi
  102. Cellex
  103. Cellmic
  104. Cepheid
  105. CerTest Biotec
  106. Chaim Sheba Medical Center
  107. Checkable Medical
  108. Chembio Diagnostic Systems
  109. Chester County Health Department
  110. CIGA Healthcare
  111. CK Life Sciences
  112. Clinton Health Access Initiative
  113. Concepta
  114. Confirm BioSciences
  115. Corgenix Medical
  116. Coris BioConcept
  117. Creative Diagnostics
  118. Credo Diagnostics Biomedical
  119. CTK Biotech
  120. Cue Health
  121. Curetis
  122. Curiosity Diagnostics
  123. Cyient
  124. Cypress Diagnostics
  125. Cytiva
  126. Datametrex AI
  127. DCL Laboratory Products
  128. DCN Diagnostics
  129. Denka
  130. Denka Seiken
  131. Diagnostic Automation / Cortez Diagnostics
  132. Diagnostics for the Real World (DRW)
  133. DIALAB
  134. DiaSorin
  135. DiscoveryDX
  136. DNA Electronics
  137. Dolomite Microfluidics
  138. Dynamiker Biotechnology (Tianjin)
  139. E25Bio
  140. Ebram Produtos Laboratoriais
  141. ECO Diagnóstica
  142. efyian
  143. Eiken Chemical
  144. Elabscience
  145. Elena Diagnostic
  146. ELG Medical
  147. Ellume
  148. EMPE Diagnostics
  149. Era Biology
  150. Eurobio Scientific
  151. Evotech-Mirai Genomics (EMG)
  152. Exhalation Medical Technology
  153. EY Laboratories
  154. FastSense Diagnostics
  155. Fio
  156. First Diagnostic
  157. Firstep Bioresearch
  158. Fluxergy
  159. Focus Diagnostics
  160. Foundation for Innovative New Diagnostics (FIND)
  161. Frontage Laboratories
  162. Frontida BioPharm
  163. Fujirebio
  164. Future HorizonS Scientific
  165. Fyodor Biotechnologies
  166. GaDia
  167. GenBody
  168. genedrive
  169. GenePOC
  170. Genesis Diagnostics
  171. GenMark Diagnostics
  172. GenPrime
  173. GENSPEED Biotech
  174. GeTein BioMedical
  175. Ginolis
  176. Glenbio
  177. GoDx
  178. Guangzhou Wondfo Biotech
  179. Hangzhou AllTest Biotech
  180. Hangzhou Biotest Biotech
  181. Hangzhou Bosure Biotech
  182. Hangzhou Genesis Biodetection & Biocontrol
  183. Hangzhou Laihe Biotech
  184. Hangzhou Testsea Biotechnology
  185. Harvard University
  186. HBI
  187. Healgen Scientific
  188. Hebei Times Medical Technology
  189. Helix2
  190. Hema Diagnostic Systems
  191. Hemex Health
  192. Henry Schein
  193. HiberGene Diagnostics
  194. HIGHTOP Biotech
  195. Human Gesellschaft für Biochemica und Diagnostica
  196. Humasis
  197. iAssay
  198. Ibn Rushd Medical & Scientific Equipment
  199. ICT Diagnostics
  200. Immunoshop
  201. Immunostics
  202. InBios International
  203. Indian Council of Medical Research
  204. InSilixa
  205. Instadiagnostics
  206. Instant NanoBiosensors
  207. Institut Pasteur de Dakar
  208. Intec Products
  209. Integrated DNA Technologies
  210. Interlab INTERAUTOMATIKA
  211. Invenio Medical
  212. J&G Biotech
  213. J. Mitra
  214. JAJ International
  215. Jiangsu Dablood Pharmaceutical
  216. JOYSBIO (Tianjin) Biotechnology
  217. KAINOS Laboratories
  218. Kephera Diagnostics
  219. Kin Diagnostics
  220. KöroÄŸlu Medical Devices
  221. Lab Care Diagnostics
  222. Lab21
  223. Labmaster
  224. Labsystems Diagnostics
  225. LamdaGen
  226. Leaflife Technology
  227. LifeSign
  228. Liming Bio-Products
  229. LT LABS
  230. Luminex
  231. Luminostics
  232. LumiraDx
  233. Lumos Diagnostics
  234. Maccura Biotechnology
  235. Mass General Brigham
  236. Massachusetts General Hospital
  237. Massachusetts Institute of Technology
  238. Maternova
  239. MBio Diagnostics
  240. MBiolog Diagnósticos
  241. McKesson Medical-Surgical
  242. Medcaptain Medical Technology
  243. Medical Communications Associates
  244. Medical Innovation Ventures
  245. MedicalSystem Biotechnology
  246. Mediclone Biotech
  247. Medimprint
  248. MEDISENSOR
  249. MedMira
  250. Medusa19
  251. Menarini Silicon Biosystems
  252. Menssana Research
  253. Meridian Bioscience
  254. Meril Life Sciences
  255. Mesa Biotech
  256. MH Medical
  257. MicrosensDx
  258. Mobidiag
  259. Mobile Assay
  260. Mokobio Biotechnology
  261. Molbio Diagnostics
  262. Mologic
  263. MONDIALAB
  264. Moroccan Foundation for Advanced Science Innovation & Research (MAScIR)
  265. Mossman Associates
  266. MP Biomedicals
  267. Mylan
  268. nal von minden
  269. Nanobiosym
  270. Nano-Ditech
  271. NanoDx
  272. NanoEnTek
  273. Nanōmix
  274. National Institute of Infectious Diseases
  275. Nectar Lifesciences
  276. NextGen Invitro Diagnostics (NGIVD)
  277. Nexus Dx
  278. NG Biotech
  279. Noul
  280. NowAware
  281. NOWDiagnostics
  282. NTBIO Diagnostics
  283. Nulife Care
  284. Oasis Diagnostics
  285. OMC Healthcare
  286. Omega Diagnostics
  287. One Milo
  288. Ontera
  289. OpGen
  290. OPKO Health
  291. Orangelife Comercio e Industria
  292. Oranoxis
  293. OraSure Technologies
  294. Orchid Biomedical Systems
  295. Oscar Medicare
  296. Owen Mumford
  297. Owlstone Medical
  298. Pacific Image Electronics
  299. PAI Life Sciences
  300. PATH
  301. PhageTech
  302. Pinakin Pharmaceuticals
  303. PointCare Technologies
  304. Prechek Bio
  305. Precision Biosensor
  306. Predictive Laboratories
  307. Premier Medical
  308. PRIMA Lab
  309. Pro Med Diagnostics
  310. Proactive Diagnostics
  311. Prominex
  312. ProteinLogic
  313. QIAGEN
  314. Qualpro Diagnostics
  315. QuantaSpec
  316. QuantuMDx
  317. Quaphaco
  318. Quartzy
  319. Quibasa-Bioclin
  320. Quidel
  321. Quimica Valaner
  322. Radiometer Medical India
  323. Randox Testing Services
  324. Rapid Biosensor Systems
  325. Rapid Diagnostics Group
  326. Rapid Diagnostics ML
  327. RapiGEN
  328. RayBiotech
  329. R-Biopharm
  330. REAGEN
  331. Relay Medical
  332. Response Biomedical
  333. Reszon Diagnostics International
  334. Rheonix
  335. Righton
  336. RINGBIO
  337. Roche
  338. ROI Scientific
  339. RPS Diagnostics
  340. Rutgers University
  341. SA Scientific
  342. Sagentia
  343. Savyon Diagnostics
  344. Scanogen
  345. SD BIOSENSOR
  346. SEASUN BIOMATERIALS
  347. Sedia Biosciences
  348. Sekisui Chemical
  349. Sekisui Diagnostics
  350. Seloi Healthcare
  351. SensDx
  352. Sense Biodetection
  353. Sepsitron
  354. Shanghai Chemtron Biotech
  355. Shanghai Kehua Bio-Engineering
  356. Shenzhen Bioeasy Biotechnology
  357. Sherlock Biosciences
  358. Sight Diagnostics
  359. SkillCell
  360. Skolkovo Institute of Science and Technology
  361. Span Biotech
  362. Spartan Bioscience
  363. SpeeDx
  364. Spindiag
  365. SSI Diagnostica
  366. Stony Brook Medicine
  367. Sugentech
  368. Sure Bio-Tech
  369. SureScreen Diagnostics
  370. Swift Molecular Diagnostics
  371. Sysmex Partec
  372. Talis Biomedical
  373. Tangen Biosciences
  374. Tata Trusts
  375. TAUNS Laboratories
  376. Technogenetics
  377. Teco Diagnostics
  378. The eNose Company
  379. The Inovie Group
  380. Theranostica
  381. Thermal Gradient
  382. Thermo Fisher Scientific
  383. TM Testing
  384. Topcare Biotech
  385. Trinity Biotech
  386. TrivTech Dx
  387. Tulip Diagnostics
  388. Turk Lab
  389. UCP Biosciences
  390. ulti med Products
  391. Unilatex.com
  392. Unimed International
  393. UNITAID
  394. United States Department of Health and Human Services (HHS)
  395. University of Oxford
  396. University of Tokyo
  397. UrSure
  398. Ustar Biotechnologies
  399. Vazyme Biotech
  400. VedaLab
  401. Veredus Laboratories
  402. Vidant Health
  403. VIDIA
  404. Viola Diagnostic Systems
  405. Vision Biotechnology
  406. VivaChek Laboratories
  407. VOGO
  408. W.H.P.M.
  409. Wageningen University & Research
  410. WAMA Diagnóstica
  411. Webb Diagnostic Technologies
  412. Wellgistics
  413. WELLS BIO
  414. Wezi Medical Center
  415. World Hepatitis Alliance
  416. Wuhan UNscience Biotechnology
  417. XCR Diagnostics
  418. Xiamen Biotime Biotechnology
  419. Xiamen Boson Biotech
  420. Xinhua Healthcare Industry
  421. Yaathum Biotech
  422. Zephyr Biomedicals
  423. Zhuhai Livzon Diagnostics
  424. ZymeTx

Source 1: www.who.int/bulletin/volumes/83/3/interview0305/en/
Source 2: www.ncbi.nlm.nih.gov/pmc/articles/PMC3722505/

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.